Vaginitis News and Research

RSS

Vaginitis is described medically as irritation and/or inflammation of the vagina. Vaginitis is a very common disease affecting millions of women each year. The three most common vaginal infections are bacterial vaginosis (BV), candida vaginitis (yeast infection) and trichomonas vaginitis ("trich").

Vaginal infections can produce a variety of symptoms, such as abnormal or increased discharge, itching, fishy odor, irritation, painful urination or vaginal bleeding. When you have vaginitis, you may have some or all of these symptoms.

Study finds AFFIRM assay may accurately detect Trichamonos vaginalis

A study from the microbiology lab at Rhode Island Hospital has found that a new test may be more accurate in identifying a common sexually transmitted infection, Trichamonos vaginalis.

8 Mar 2011

New study: Asthma may have relationship with airway microbiota composition

Asthma may have a surprising relationship with the composition of the species of bacteria that inhabit bronchial airways, a finding that could suggest new treatment or even potential cures for the common inflammatory disease, according to a new UCSF-led study.

18 Feb 2011

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

Gen-Probe submits 510(k) application to FDA for APTIMA Trichomonas vaginalis assay on TIGRIS system

Gen-Probe Incorporated announced today that the Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

5 Oct 2010

Scientists to identify microbial risk predictors for preterm birth

A team of scientists from Mayo Clinic, the University of Illinois at Urbana-Champaign, and the J. Craig Venter Institute are leveraging a long-standing research relationship to apply results from the Human Microbiome Project to help identify microbial risk predictors for preterm birth.

29 Sep 2010

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

China Sky One Medical receives SFDA approval for producing Ciclopirox Olamine Vaginal Suppositories

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced that the Company has obtained approval from the State Food and Drug Administration in China for the production of Ciclopirox Olamine Vaginal Suppositories.

23 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

Big Ow awareness campaign

When it comes to symptoms of menopause like hot flashes, weight gain or trouble sleeping, chances are most women wouldn't hesitate to speak to their doctor. But there is another common - and equally distressing - effect of menopause that many women just keep to themselves. The Big Ow, also known as vaginal atrophy, will affect as many as two million Canadian women in the next 10 years - but most are too shy or embarrassed to talk about it, even with their doctor.

8 Feb 2010

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Researchers from the University of Pennsylvania and the University of Georgia have been awarded a five-year, $14.6 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health, to expand and extend work on the Eukaryotic Pathogen Genome Database Resource, http://EuPathDB.org.

11 Dec 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

New strategy to treat human infections caused by the yeast Candida albicans

Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.

27 Oct 2008

Everything that itches isn't a yeast infection!

Most women who think they have a vaginal yeast infection are wrong and may be doing more harm than good in treating their problem, says a Saint Louis University researcher who presented her findings recently.

11 Sep 2007

FDA approves treatment for bacterial vaginosis

Mission Pharmacal has announced that the U.S. Food and Drug Administration (FDA) approved Tindamax (tinidazole) for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

28 May 2007

No apparent increase in coronary heart disease for women who initiate hormone therapy

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE ) , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association.

4 Apr 2007

Warning of risk of from vaginal oestrogen

Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane.

26 Jan 2006

Specific bacterial markers for bacterial vaginosis discovered

Findings reported in this week's New England Journal of Medicine (November 3 issue) highlight promising findings from two Seattle-based researchers on the origins of bacterial vaginosis (BV).

7 Nov 2005